AR063120A1 - Composiciones inyectables de deposito y proceso para prepararlas - Google Patents
Composiciones inyectables de deposito y proceso para prepararlasInfo
- Publication number
- AR063120A1 AR063120A1 ARP070104388A ARP070104388A AR063120A1 AR 063120 A1 AR063120 A1 AR 063120A1 AR P070104388 A ARP070104388 A AR P070104388A AR P070104388 A ARP070104388 A AR P070104388A AR 063120 A1 AR063120 A1 AR 063120A1
- Authority
- AR
- Argentina
- Prior art keywords
- component
- optionally
- active agent
- compositions
- mixing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Composiciones inyectables de deposito que comprenden al menos un agente activo, opcionalmente con uno o.más excipientes farmacéuticamente aceptables en forma de un sistema de componentes multiples que comprende preferiblemente al menos dos componentes que, al ser suministrados a un individuo que los necesita, forma un deposito de gel in situ o implante en el lugar de la inyeccion tras el contacto con fluidos corporales y exhibe una liberacion prolongada del agente activo. Proceso para preparacion de tales composiciones y métodos para usar dichas composiciones. Reivindicacion 4: Una composicion tal como se reivindica en la reivindicacion 1, caracterizada porque el agente activo se selecciona de un grupo que comprende anastrozola, lentrozola, tamsulosin, donepezil, aripiprazol, olanzapina, risperidona y ziprasidona. Reivindicacion 25: Un proceso para la preparacion de una composicion inyectable tal como se reivindica en la reivindicacion 7, caracterizado por comprender los siguientes pasos: i) mezclar el agente(s) activo con polímero(s) biodegradable para formar micropartículas o nanopartículas, (ii) mezclas las micropartículas o nanopartículas del paso (i) opcionalmente con agente(s) mejoradotes de la viscosidad y/u opcionalmente con uno o más excipientes para formar el componente 1, (iii) mezclar el vehículo líquido opcionalmente con agente(s) mejorador(es) de la viscosidad y/u otros excipientes para formar el componente 2, y (iv) mezclar el componente 1 y el componente 2 para obtener el compuesto deseado antes de la administracion.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2195DE2006 | 2006-10-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR063120A1 true AR063120A1 (es) | 2008-12-30 |
Family
ID=39268891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070104388A AR063120A1 (es) | 2006-10-05 | 2007-10-03 | Composiciones inyectables de deposito y proceso para prepararlas |
Country Status (17)
Country | Link |
---|---|
US (2) | US20100015195A1 (es) |
EP (2) | EP2089000A2 (es) |
JP (2) | JP2010505821A (es) |
KR (2) | KR20090087441A (es) |
CN (2) | CN101541316A (es) |
AR (1) | AR063120A1 (es) |
AU (2) | AU2007303794A1 (es) |
BR (2) | BRPI0718288A2 (es) |
CA (2) | CA2665105A1 (es) |
CL (1) | CL2007002851A1 (es) |
EA (1) | EA200970348A1 (es) |
IL (2) | IL197947A0 (es) |
MA (2) | MA30814B1 (es) |
MX (2) | MX2009003737A (es) |
RU (1) | RU2009116933A (es) |
TN (2) | TN2009000125A1 (es) |
WO (2) | WO2008041246A2 (es) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
EP2526996B1 (en) | 2002-12-20 | 2019-09-11 | Xeris Pharmaceuticals, Inc. | Formulation for intracutaneous injection |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
US9205046B2 (en) * | 2005-04-25 | 2015-12-08 | The Governing Council Of The University Of Toronto | Enhanced stability of inverse thermal gelling composite hydrogels |
US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
WO2008021133A2 (en) | 2006-08-09 | 2008-02-21 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies |
EP2157967B1 (en) | 2007-04-23 | 2013-01-16 | Intarcia Therapeutics, Inc | Suspension formulations of insulinotropic peptides and uses thereof |
CN101801415B (zh) | 2007-05-25 | 2015-09-23 | Rb医药品有限公司 | 利培酮化合物的持续递送制剂 |
MX2009013663A (es) * | 2007-06-22 | 2010-01-27 | Scidose Llc | Formulacion solubilizada de docetaxel sin tween 80. |
ES2529746T3 (es) * | 2007-06-25 | 2015-02-25 | Otsuka Pharmaceutical Co., Ltd. | Microesferas con una estructura de núcleo/cáscara |
CL2008003305A1 (es) * | 2007-11-06 | 2009-06-05 | M/S Panacea Biotec Ltd | Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer. |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
US9180088B2 (en) | 2008-03-07 | 2015-11-10 | Scidose, Llc | Fulvestrant formulations |
US8524267B2 (en) * | 2008-04-18 | 2013-09-03 | Warsaw Orthopedic, Inc. | Dexamethasone formulations in a biodegradable material |
CN101569622B (zh) * | 2008-04-30 | 2012-11-21 | 天津药物研究院 | 一种用于注射给药的药物制剂及其制备方法 |
EA014044B1 (ru) * | 2008-07-09 | 2010-08-30 | Общество С Ограниченной Ответственностью "Аква-Альянс" | Наносомальная лекарственная форма препарата пролонгированного действия для лечения гепатита с (варианты) |
AU2009289529B2 (en) * | 2008-09-04 | 2015-05-28 | Amylin Pharmaceuticals, Llc | Sustained release formulations using non-aqueous carriers |
CN102281870B (zh) | 2008-12-10 | 2015-03-04 | 安徽中人科技有限责任公司 | 新型控释组合物 |
WO2010093945A2 (en) | 2009-02-13 | 2010-08-19 | Glaukos Corporation | Uveoscleral drug delivery implant and methods for implanting the same |
CA2754200A1 (en) * | 2009-03-02 | 2010-09-10 | Assistance Publique - Hopitaux De Paris | Injectable biomaterial |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
CN104323981B (zh) | 2009-09-28 | 2019-03-12 | 精达制药公司 | 基本稳态药物递送的快速建立和/或终止 |
CN101669942A (zh) * | 2009-09-29 | 2010-03-17 | 北京华禧联合科技发展有限公司 | 难溶性药物组合物 |
US8912228B2 (en) | 2009-10-19 | 2014-12-16 | Scidose Llc | Docetaxel formulations with lipoic acid |
US20110092579A1 (en) * | 2009-10-19 | 2011-04-21 | Scidose Llc | Solubilized formulation of docetaxel |
US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
US8541465B2 (en) * | 2009-10-19 | 2013-09-24 | Scidose, Llc | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid |
US8476310B2 (en) | 2009-10-19 | 2013-07-02 | Scidose Llc | Docetaxel formulations with lipoic acid |
US9504698B2 (en) * | 2009-10-29 | 2016-11-29 | Warsaw Orthopedic, Inc. | Flowable composition that sets to a substantially non-flowable state |
RU2548753C2 (ru) | 2009-11-16 | 2015-04-20 | Ипсен Фарма С.А.С. | Фармацевтические композиции лигандов рецепторов меланокортинов |
EP2547351B1 (en) * | 2010-03-15 | 2016-04-27 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of growth hormone secretagogue receptor ligands |
RU2012145811A (ru) * | 2010-03-29 | 2014-05-10 | Евоник Корпорейшн | Композиции и способы улучшенного удержания фармацевтической композиции на участке местного введения |
US10335366B2 (en) * | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
ES2390439B1 (es) | 2012-08-03 | 2013-09-27 | Laboratorios Farmacéuticos Rovi, S.A. | Composición inyectable |
US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
DE102010023949A1 (de) * | 2010-06-16 | 2011-12-22 | F. Holzer Gmbh | In-situ Lecithin-Mikroemulsionsgel-Formulierung |
US20120046225A1 (en) | 2010-07-19 | 2012-02-23 | The Regents Of The University Of Colorado, A Body Corporate | Stable glucagon formulations for the treatment of hypoglycemia |
CA2796755C (en) * | 2010-08-24 | 2015-10-27 | Otsuka Pharmaceutical Co., Ltd. | Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative |
US9757374B2 (en) | 2010-10-28 | 2017-09-12 | Aequus Pharmaceuticals Inc. | Aripiprazole compositions and methods for its transdermal delivery |
JP5966228B2 (ja) * | 2010-10-28 | 2016-08-10 | アエクース ファーマシューティカルズ インコーポレイテッドAequus Pharmaceuticals Inc | アリピプラゾール組成物 |
EP2654715B1 (en) | 2010-11-24 | 2017-01-25 | Dose Medical Corporation | Drug eluting ocular implant |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
SG193389A1 (en) | 2011-03-10 | 2013-10-30 | Xeris Pharmaceuticals Inc | Stable formulations for parenteral injection of peptide drugs |
US9034867B2 (en) * | 2011-03-18 | 2015-05-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising sorbitan esters |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
CN103930096B (zh) | 2011-10-31 | 2017-05-31 | Xeris药物公司 | 用于治疗糖尿病的制剂 |
US11179468B2 (en) | 2012-04-09 | 2021-11-23 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations |
JOP20200109A1 (ar) * | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
EP2705835A1 (en) * | 2012-06-08 | 2014-03-12 | Ipsen Pharma S.A.S. | Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release |
CN103483353B (zh) * | 2012-06-13 | 2016-02-24 | 上海现代药物制剂工程研究中心有限公司 | 二硫杂环戊烯并吡咯酮化合物的纳米粒及制备方法 |
US9125805B2 (en) | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
KR101811797B1 (ko) * | 2013-04-03 | 2017-12-22 | 동국제약 주식회사 | 도네페질을 포함하는 비경구투여용 약제학적 조성물 |
US9949928B2 (en) * | 2013-05-01 | 2018-04-24 | The Regents Of The University Of Colorado, A Body Corporate | Biodegradable copolymers, systems including the copolymers, and methods of forming and using same |
US20160200891A1 (en) * | 2013-08-22 | 2016-07-14 | Polyvalor Limited Partnership | Porous gels and methods for their preparation |
JP2015093854A (ja) * | 2013-11-12 | 2015-05-18 | 株式会社クレハ | 水性組成物および加水分解抑制方法 |
CH708890B1 (de) * | 2013-11-22 | 2018-03-15 | Sandel Thomas | Ball, vorzugsweise Golfball, sowie ein mit dem Ball kommunizierbares elektronisches Gerät. |
US20150174254A1 (en) | 2013-12-23 | 2015-06-25 | Mcneil-Ppc, Inc. | Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent |
GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
EP3148491B1 (en) | 2014-05-29 | 2020-07-01 | Glaukos Corporation | Implants with controlled drug delivery features and manufacturing method for said implants |
CA2957399C (en) | 2014-08-06 | 2023-09-26 | Xeris Pharmaceuticals, Inc. | Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
KR20170083108A (ko) * | 2014-11-10 | 2017-07-17 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | C형 간염에 대한 장기 작용 약학적 조성물 |
EP3028721A1 (en) * | 2014-12-05 | 2016-06-08 | Exchange Imaging Technologies GmbH | Nanoparticle formulation having reverse-thermal gelation properties for injection |
KR101692314B1 (ko) * | 2015-03-27 | 2017-01-03 | 주식회사 주빅 | 지용성 약물의 생분해성 고분자 내 용해 시스템: 스마트 폴리머 시스템 |
US9844558B1 (en) | 2015-04-30 | 2017-12-19 | Amag Pharmaceuticals, Inc. | Methods of reducing risk of preterm birth |
WO2016196851A2 (en) | 2015-06-03 | 2016-12-08 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
EP3373907A4 (en) * | 2015-11-11 | 2019-12-18 | Qrono, Inc. | EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE |
WO2017105512A1 (en) * | 2015-12-18 | 2017-06-22 | Proinvet Innovations S.A. | Formulations and methods for controlling the reproductive cycle and ovulation |
CN115120405A (zh) | 2016-04-20 | 2022-09-30 | 多斯医学公司 | 生物可吸收眼部药物的递送装置 |
WO2017200987A1 (en) * | 2016-05-16 | 2017-11-23 | Amag Pharmaceuticals, Inc. | Polymeric extended release compositions of hydroxyprogesterone caproate and methods of using same |
MX2018014016A (es) | 2016-05-16 | 2019-08-01 | Intarcia Therapeutics Inc | Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos. |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
WO2018015915A1 (en) * | 2016-07-22 | 2018-01-25 | Cadila Healthcare Limited | A parenteral controlled release composition of an atypical antipsychotic agent |
CN110225762A (zh) | 2017-01-03 | 2019-09-10 | 因塔西亚制药公司 | 包括glp-1受体激动剂的连续施用和药物的共同施用的方法 |
EP3573747A4 (en) * | 2017-01-23 | 2020-12-30 | Savior Lifetec Corporation | PREPARATION OF MICROPARTICLES OF AN ACTIVE SUBSTANCE |
CN106822043A (zh) * | 2017-01-24 | 2017-06-13 | 广州帝奇医药技术有限公司 | 利培酮缓释组合物及其制备方法 |
CN106822039A (zh) * | 2017-01-24 | 2017-06-13 | 广州帝奇医药技术有限公司 | 水难溶或微溶性药物缓释组合物及其制备方法 |
CN106822042A (zh) * | 2017-01-24 | 2017-06-13 | 广州帝奇医药技术有限公司 | 一种利培酮缓释组合物及其制备方法 |
CN106727422B (zh) * | 2017-03-09 | 2018-10-02 | 王秋玉 | 一种聚对二氧环己酮为核的核-壳双层微球及其制备方法和应用 |
WO2018222922A1 (en) | 2017-06-02 | 2018-12-06 | Xeris Pharmaceuticals, Inc. | Precipitation resistant small molecule drug formulations |
AU2018329202B2 (en) | 2017-09-11 | 2022-10-27 | Atossa Therapeutics, Inc. | Methods for making and using endoxifen |
KR20200091385A (ko) | 2017-09-15 | 2020-07-30 | 옥슬러 리미티드 | 안과용 전달 장치 |
PL3562485T3 (pl) * | 2018-03-23 | 2020-11-16 | Laboratoires Major | Niehormonalne kompozycje i sposoby antykoncepcji u mężczyzn z wykorzystaniem (r)-silodozyny |
PE20210047A1 (es) | 2018-06-12 | 2021-01-08 | Farm Rovi Lab Sa | Composicion inyectable |
JP2021534242A (ja) * | 2018-08-10 | 2021-12-09 | エフェメラル ソリューションズ,インコーポレイテッド | 着色剤を含有する粒子及びその使用方法 |
US11896715B2 (en) | 2019-06-21 | 2024-02-13 | Korea University Research And Business Foundation | In vivo bulking agent, injection comprising same, and preparation method therefor |
CN111388744B (zh) * | 2020-01-15 | 2021-05-18 | 华中科技大学 | 一种凝胶贮库及其制法与制备术后止血制剂的应用 |
CN111956599B (zh) * | 2020-09-29 | 2023-02-17 | 江苏集萃新型药物制剂技术研究所有限公司 | 皮下植入药剂及其组合物和制备方法 |
KR102266384B1 (ko) * | 2021-01-25 | 2021-06-21 | 주식회사 울트라브이 | 필러용 생분해성 고분자 미세입자, 이를 포함한 필러용 동결건조체, 그 제조방법 및 상기 동결건조체를 포함하는 필러용 주사제 |
KR102652905B1 (ko) * | 2021-08-09 | 2024-04-01 | 주식회사 메디폴리머 | 주사용 사전-제형 및 이를 이용한 도네페질 초기방출 억제형 키트 |
TW202313047A (zh) | 2021-09-21 | 2023-04-01 | 西班牙商禾霏藥品實驗室有限公司 | 抗精神病可注射儲積型組合物 |
WO2024151625A1 (en) * | 2023-01-10 | 2024-07-18 | Georgetown University | Non-toxic plga compositions and methods of making and using same |
CN116850146B (zh) * | 2023-05-22 | 2024-05-14 | 济南大学 | 伏硫西汀自由碱或其药用盐长效缓释制剂及其制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5242910A (en) * | 1992-10-13 | 1993-09-07 | The Procter & Gamble Company | Sustained release compositions for treating periodontal disease |
ATE188375T1 (de) * | 1992-11-17 | 2000-01-15 | Yoshitomi Pharmaceutical | Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung |
US5650173A (en) * | 1993-11-19 | 1997-07-22 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
GB9718986D0 (en) * | 1997-09-09 | 1997-11-12 | Danbiosyst Uk | Controlled release microsphere delivery system |
WO2002058672A2 (en) * | 2001-01-26 | 2002-08-01 | Debio Recherche Pharmaceutique S.A. | Microparticles of biodegradable polymer encapsulating a biologically active substance |
BRPI0213226B1 (pt) * | 2001-10-10 | 2016-03-01 | Pf Medicament | processo de preparação de uma composição farmacêutica sob forma de microesferas com liberação prolongada de um princípio ativo hidrossolúvel, e, microesferas |
TW200719903A (en) * | 2005-04-19 | 2007-06-01 | Combinatorx Inc | Compositions for the treatment of neoplasms |
-
2007
- 2007-10-03 CA CA002665105A patent/CA2665105A1/en not_active Abandoned
- 2007-10-03 AU AU2007303794A patent/AU2007303794A1/en not_active Abandoned
- 2007-10-03 US US12/444,197 patent/US20100015195A1/en not_active Abandoned
- 2007-10-03 KR KR1020097009284A patent/KR20090087441A/ko not_active Application Discontinuation
- 2007-10-03 BR BRPI0718288-0A2A patent/BRPI0718288A2/pt not_active Application Discontinuation
- 2007-10-03 CA CA002665101A patent/CA2665101A1/en not_active Abandoned
- 2007-10-03 EP EP07827594A patent/EP2089000A2/en not_active Withdrawn
- 2007-10-03 EA EA200970348A patent/EA200970348A1/ru unknown
- 2007-10-03 KR KR1020097009289A patent/KR20090094811A/ko active IP Right Grant
- 2007-10-03 EP EP07827598A patent/EP2086505A2/en not_active Withdrawn
- 2007-10-03 JP JP2009531016A patent/JP2010505821A/ja not_active Withdrawn
- 2007-10-03 RU RU2009116933/15A patent/RU2009116933A/ru not_active Application Discontinuation
- 2007-10-03 AR ARP070104388A patent/AR063120A1/es unknown
- 2007-10-03 CL CL2007002851A patent/CL2007002851A1/es unknown
- 2007-10-03 AU AU2007303793A patent/AU2007303793A1/en not_active Abandoned
- 2007-10-03 MX MX2009003737A patent/MX2009003737A/es not_active Application Discontinuation
- 2007-10-03 CN CNA2007800441356A patent/CN101541316A/zh active Pending
- 2007-10-03 JP JP2009531014A patent/JP2010505819A/ja not_active Withdrawn
- 2007-10-03 WO PCT/IN2007/000473 patent/WO2008041246A2/en active Application Filing
- 2007-10-03 CN CNA2007800441089A patent/CN101541313A/zh active Pending
- 2007-10-03 MX MX2009003735A patent/MX2009003735A/es unknown
- 2007-10-03 US US12/444,257 patent/US20100098735A1/en not_active Abandoned
- 2007-10-03 WO PCT/IN2007/000454 patent/WO2008041245A2/en active Application Filing
- 2007-10-03 BR BRPI0720346-2A2A patent/BRPI0720346A2/pt not_active IP Right Cessation
-
2009
- 2009-04-03 TN TNP2009000125A patent/TN2009000125A1/fr unknown
- 2009-04-03 TN TNP2009000124A patent/TN2009000124A1/fr unknown
- 2009-04-05 IL IL197947A patent/IL197947A0/en unknown
- 2009-04-05 IL IL197946A patent/IL197946A0/en unknown
- 2009-04-27 MA MA31821A patent/MA30814B1/fr unknown
- 2009-04-27 MA MA31824A patent/MA30817B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
RU2009116933A (ru) | 2010-11-10 |
CL2007002851A1 (es) | 2008-01-18 |
KR20090087441A (ko) | 2009-08-17 |
US20100015195A1 (en) | 2010-01-21 |
CA2665105A1 (en) | 2008-04-10 |
BRPI0718288A2 (pt) | 2013-11-19 |
CN101541316A (zh) | 2009-09-23 |
JP2010505819A (ja) | 2010-02-25 |
JP2010505821A (ja) | 2010-02-25 |
IL197947A0 (en) | 2009-12-24 |
EP2086505A2 (en) | 2009-08-12 |
AU2007303794A1 (en) | 2008-04-10 |
MA30817B1 (fr) | 2009-10-01 |
EP2089000A2 (en) | 2009-08-19 |
MA30814B1 (fr) | 2009-10-01 |
CN101541313A (zh) | 2009-09-23 |
CA2665101A1 (en) | 2008-04-10 |
TN2009000124A1 (en) | 2010-10-18 |
WO2008041245A2 (en) | 2008-04-10 |
IL197946A0 (en) | 2009-12-24 |
MX2009003735A (es) | 2009-04-22 |
WO2008041245A3 (en) | 2008-05-22 |
WO2008041246A2 (en) | 2008-04-10 |
TN2009000125A1 (en) | 2010-10-18 |
AU2007303793A1 (en) | 2008-04-10 |
WO2008041246A3 (en) | 2008-05-29 |
US20100098735A1 (en) | 2010-04-22 |
KR20090094811A (ko) | 2009-09-08 |
EA200970348A1 (ru) | 2009-10-30 |
BRPI0720346A2 (pt) | 2014-06-24 |
MX2009003737A (es) | 2009-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR063120A1 (es) | Composiciones inyectables de deposito y proceso para prepararlas | |
HRP20180118T1 (hr) | Injekcijski tekući pripravak koji sadrži buprenorfin | |
ES2524320T3 (es) | Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo | |
WO2009044403A3 (en) | Injectable biodegradable polymer compositions for soft tissue repair and augmentation | |
AR070033A1 (es) | Composiciones inyectables, sus procesos y usos | |
AR041913A1 (es) | Formulaciones de deposito de liberacion controlada | |
JP2013533230A5 (es) | ||
MY161930A (en) | Antipsychotic injectable depot composition | |
BRPI0514297A (pt) | composições farmacêuticas para liberação controlada de compostos biologicamente ativos | |
BR112015017246A2 (pt) | formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel | |
AR060487A1 (es) | Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40 | |
PE20060003A1 (es) | Formulacion farmaceutica polimerica para moldear por inyeccion | |
BR112012030457A2 (pt) | processo para fabricar uma composição hesmostática seca e estável, método para entregar uma composição hemostática a um sítio alvo e para prover uma composição hemostática pronta para uso, recipiente acabado final, e, kit para administra uma composição hemostática | |
HRP20161138T1 (hr) | Farmaceutski pripravak za oralnu primjenu | |
BR112014013691A2 (pt) | pré-formulação, métodos para distribuição de um agente ativo de peptídeo, para a preparação de uma composição cristalina líquida, de tratamento ou profilaxia de um sujeito, processo para a formação de uma pré-formulação, uso de uma mistura cristalina não líquida de baixa viscosidade, dispositivo de administração de pré-preenchido, e, kit | |
CR9704A (es) | Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma. | |
WO2007084460A3 (en) | Pharmaceutical compositions with enhanced stability | |
BR112013027674A2 (pt) | "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha". | |
NZ627368A (en) | Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation | |
AR072668A1 (es) | Encapsulacion de agentes biologicamente activos | |
AR082566A1 (es) | Formulaciones liquidas de st-246 y metodos relacionados, proceso | |
WO2007111945A3 (en) | Method for management of diarrhea | |
BR112016001544A2 (pt) | composições farmacêuticas para injeção intraocular compreendendo agentes anti-bacteriano e anti-inflamatório, seu método de preparação, kit farmacêutico e uso dos referidos agentes no preparo das referidas composições farmacêuticas | |
JP2018510894A5 (es) | ||
AR066677A1 (es) | Formulacion de pasireotida. composicion farmaceutica para liberacion prolongada. microparticulas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |